Holen Sie sich die Stockscreener-App
11.61
1.13%
0.13
Handel nachbörslich:
11.37
-0.24
-2.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$11.48
Offen:
$11.48
24-Stunden-Volumen:
2.27M
Relative Volume:
0.66
Marktkapitalisierung:
$1.50B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-18.73
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+13.60%
1M Leistung:
+8.81%
6M Leistung:
+56.68%
1J Leistung:
-29.16%
1-Tages-Spanne:
$11.27
$11.66
1-Wochen-Bereich:
$9.89
$11.66
52-Wochen-Spanne:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
11.61 | 1.49B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know - TradingView
First Week of January 2026 Options Trading For NeoGenomics (NEO) - Nasdaq
How NeoGenomics Inc. stock compares to market leadersWeekly Trade Review & Weekly Top Gainers Trade List - newser.com
Can NeoGenomics Inc. (NG9) stock sustain revenue momentumJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
How hedge fund analytics apply to NeoGenomics Inc. stock2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Is NeoGenomics Inc. stock a buy on dipsLayoff News & Smart Swing Trading Techniques - newser.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in NeoGenomics, Inc. $NEO - MarketBeat
Is NeoGenomics Inc. (NG9) stock cheap by valuation metricsDividend Hike & Proven Capital Preservation Tips - newser.com
Earnings visualization tools for NeoGenomics Inc.2025 Earnings Impact & High Conviction Trade Alerts - newser.com
Is NeoGenomics Inc. (NG9) stock attractive for growth fundsMarket Activity Report & Daily Profit Focused Stock Screening - newser.com
Will NeoGenomics Inc. (NG9) stock beat value stocksJuly 2025 Snapshot & Smart Allocation Stock Tips - newser.com
Will earnings trigger a reversal in NeoGenomics Inc.Buy Signal & Safe Capital Growth Plans - newser.com
Will NeoGenomics Inc. (NG9) stock beat Nasdaq index returns2025 Historical Comparison & Precise Swing Trade Entry Alerts - newser.com
NeoGenomics at Stephens Conference: Strategic Growth Amid Pharma Challenges By Investing.com - Investing.com Canada
Will NeoGenomics Inc. stock maintain dividend yieldTrade Risk Report & Growth Oriented Trade Recommendations - newser.com
Price momentum metrics for NeoGenomics Inc. explainedJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Will NeoGenomics Inc. (NG9) stock announce a stock split2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Developing predictive dashboards with NeoGenomics Inc. dataMarket Risk Analysis & Long-Term Safe Investment Ideas - newser.com
Sector ETF performance correlation with NeoGenomics Inc.IPO Watch & Weekly Market Pulse Alerts - newser.com
How risky is NeoGenomics Inc. stock nowMarket Performance Summary & Verified Momentum Stock Alerts - newser.com
Avoiding Lag: Real-Time Signals in (NEO) Movement - news.stocktradersdaily.com
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):